Segunda edición: 10 de abril 2020
Panorama de la situación en Venezuela y esfuerzos hasta la fecha
NB: desde la primera iteración de este Plan se ha observado el aumento de retornos de personas a Venezuela, principalmente entrando por vía terrestre desde Colombia, lo que requiere un esfuerzo e...special desde el punto de vista de control epidemiológico, estableciendo condiciones de alojamiento temporal adecuadas y de protección, lo que se refleja en esta segunda edición.
more
10 May 2021
This scientific brief replaces the WHO Scientific Brief entitled “’Immunity passports’ in the context of COVID-19”, published 24 April 2020.
This update is focused on what is currently understood about SARS-CoV-2 immunity from natural infection. More information about considera...tions on vaccine certificates or “passports” will be covered in an update of WHO interim guidance, as requested by the COVID-19 emergency committee.
more
The Covid-19 pandemic has the significant potential to affect the quality and scale up of nutrition, health and other lifesaving interventions. The restrictions on mobility and recommendations on social distancing will affect the way we work in our nutrition programmes and measures are needed to mit...igate the potential negative impact.
more
This guidance note is meant to assist humanitarian actors, youth-led organizations, and young people themselves across sectors, working at local, country, regional, and global levels in their response to the novel coronavirus pandemic. It begins diagnostically, exploring the impacts of coronavirus d...isease (COVID-19) on young people. It then proposes a series of actions that practitioners and young people can take to ensure that COVID-19 preparedness, response plans and actions, are youth-inclusive and youth-focused – with and for young people. Recommendations are structured around the five key actions of the Compact for Young People in Humanitarian Action: services, participation, capacity, resources, and data. Where available, the recommended actions are accompanied by resources and concrete examples, which can inform approaches and support implementation
more
We as a large world community are facing an extraordinary challenge: keeping healthy against the threat of rapidly spreading novel Covid-19 virus. Starting with flu-like symptoms, the virus attacks the airways leading to severe breathing difficulties in the m ost vulnerable, that is, those whose im ...m unity is decreased because of various reasons: age over 65, living with chronic illness, taking im m unity reducing medicines. Rapid spread of the virus along with severity of its sym ptom s led health specialists to recommend social distancing, confinement and thorough hand washing to our governm ents who took actions to implement these guidelines.
more
Resources and Situation Updates COVID-19
The COVID-19 outbreak has restricted global mobility, whilst heightening the risk of exploitation of vulnerable populations. This report provides a snapshot of the COVID-19 epidemiological situation and mobility restrictions, and of the current migration trends along the Eastern Corridor migration r...oute, in addition to an analysis of the impact that movement restrictions have had in Djibouti, Ethiopia, Somalia, and Yemen. Moreover, it provides information on the main protection concerns for migrants and assistance provided, and COVID-19 risk mitigation measures. This report utilizes data collected through IOM’s Displacement Tracking Matrix (DTM) Flow Monitoring Points (FMPs), Migrant Response Centres (MRCs), Assisted Voluntary Return (AVR) data, as well as anecdotal information provided by IOM team members working in the region.
more
04.März 2021
MEDBOX Issue Brief no. 10
Dieser Issue Brief gibt einen kurzen Überblick über Teststrategie, Testverfahren, Videos zur Handhabung und weiterführende Literatur.
10 May 2021. Manufactureres:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
The ChAdOx1-S/nCoV-19 [recombinant] vaccine is a replication-deficient adenoviral vecto...r vaccine against coronavirus disease 2019 (COVID-19). The vaccine expresses the SARS-CoV-2 spike protein gene, which instructs the host cells to produce the protein of the S-antigen unique to SARS-CoV-2, allowing the body to generate an immune response and to retain that information in memory immune cells. Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) irrespective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
more
A report demonstrating the urgent need to support groups at the local level if COVID-19 misinformation and mistrust is to be tackled effectively.
As vacinas COVID-19 devem ser armazenadas, transportadas e manuseadas em condições adequadas. Isso
inclui a manutenção das condições da cadeia de frio de acordo com a recomendação da lista de uso de
emergência (EUL) e conforme especificado no folheto do produto1. Cada vez que uma vacina... é exposta a
condições inadequadas, como superexposição ao calor, ao frio ou à luz, sua potência é reduzida. Essa perda
é cumulativa e irreversível. Uma vez perdida, a potência da vacina não pode ser restaurada. O monitor do
frasco da vacina ou VVM é um indicador confiável que registra se a exposição cumulativa ao calor atingiu
um ponto em que a vacina não possa mais ser usada
more
Comirnaty® 10 μg und 30 μg von BioNTech / Pfizer und Spikevax® von Moderna
Stand 21. Dezember 2021
Comirnaty® 10 μg und 30 μg von BioNTech / Pfizer und Spikevax® von Moderna
Recommendations for in-patient management of COVID-19 in adult patients
Version 10, November 2020.
Annals of Medicine and Surgery, 79 (2022)104033
The Infection prevention and control in the context of coronavirus disease 2019 (COVID-19): a living guideline consolidates technical guidance developed and published during the COVID-19 pandemic into evidence-informed recommendations for infection prevention and control (IPC). This living guideline... is available both online and PDF.
**This version of the living guideline (version 5.0) **includes the following seven revised statements for the prevention, identification and management of SARS-CoV-2 infections among health and care workers:
a good practice statement on national and subnational testing strategies;
a good practice statement on passive syndromic surveillance of health and care workers;
a good practice statement on prioritizing health and care workers for SARS-CoV-2 testing;
a good practice statement on protocols for reporting and managing health and care worker exposures;
a good practice statement to limit in-person work of health and care workers with active SARS-CoV-2 infections;
a statement on high-risk exposures and quarantine; and,
a conditional recommendation on the duration of isolation for health and care workers.
Understanding the updated section
Prevention of infections in the health care setting includes a multi-pronged and multi-factorial approach that includes IPC and occupational health and safety measures and adherence to Public Health and Social Measures in the community by the health workforce. The underlying infection prevention and control strategy of this section is the notion that early identification of symptomatic cases, testing and quarantining/isolating health and care workers decreases the risk of nosocomial infection to patients and to other health and care workers.
more